Document:

exv10w1

Exhibit 10.1

AGREEMENT AND PLAN OF MERGER

MERGING

BANC OF AMERICA SECURITIES HOLDINGS CORPORATION

INTO

MERRILL LYNCH & CO., INC.

     THIS AGREEMENT AND PLAN OF MERGER dated November 1, 2010, made by and between MERRILL LYNCH &
CO., INC. and BANC OF AMERICA SECURITIES HOLDINGS CORPORATION, said two business entities being
hereinafter sometimes referred to as Survivor and Absorbed, respectively, or, together as the
Constituent Companies, WITNESSETH THAT:

     WHEREAS, Survivor is a corporation organized and existing under the laws of the State of
Delaware with its principal office in the State of North Carolina being located at 100 North Tryon
Street, Charlotte, NC 28255; and

     WHEREAS, Absorbed is a corporation organized and existing under the laws of the State of
Delaware with its principal office in the State of North Carolina being located at 100 North Tryon
Street, Charlotte, NC 28255; and

     WHEREAS, the board of directors and shareholders of the Constituent Companies have determined
that it is advisable that Absorbed be merged into Survivor, on the terms and conditions hereinafter
set forth, in accordance with the applicable provisions of the laws of the State of Delaware, which
laws permit such merger;

     NOW, THEREFORE, in consideration of the promises and of the mutual agreements, covenants and
provisions hereinafter contained, the parties hereto agree that Absorbed be merged into Survivor,
and that the terms and conditions of such merger, the mode of carrying the same into effect, and
the manner and basis of disposing of the capital stock of Absorbed shall be as follows:

Section 1. Absorbed and Survivor shall be merged into a single corporation, in accordance
with the applicable provisions and laws of the State of Delaware, by Absorbed merging into
Survivor, which shall be the surviving corporation. The separate existence of Absorbed
shall cease and the existence of Survivor shall continue unaffected and unimpaired by the
merger with all rights, privileges, immunities and powers, and subject to all duties and
liabilities of a corporation organized under the Delaware General Corporation Laws.

Section 2.

	 	a.	 	The Certificate of Incorporation of Survivor shall continue to
be its Certificate of Incorporation following the Effective Date (as defined
below) of the merger, until the same shall be altered or amended.
	 
	 	b.	 	The Bylaws of Survivor shall be and remain the Bylaws of
Survivor until altered, amended or repealed.

 

 

	 	c.	 	The directors and officers of Survivor in office on the
Effective Date of the merger shall continue in office and shall constitute the
directors and officers of Survivor for the term elected until their respective
successors shall be elected or appointed and qualified.

Section 3. On the Effective Date of the merger:

	 	a.	 	Survivor shall possess all the rights, privileges, immunities,
powers and franchises of a public as well as of a private nature, and shall be
subject to all of the restrictions, disabilities and duties of each of the
Constituent Companies; and all property, real, personal and mixed, including
all patents, applications for patents, trademarks, trademark registrations and
applications for registration of trademarks, together with the goodwill of the
business in connection with which said patents and marks are used, and all
debts due on whatever account, including subscriptions to shares of capital
stock, and all other choses in action and all and every other interest of or
belonging to or due to each of the Constituent Companies shall be deemed to be
transferred to and vested in Survivor without further act or deed, and the
title to any real estate, or any interest therein, vested in either of the
Constituent Companies shall not revert or be in any way impaired by reason of
the merger.
	 
	 	b.	 	Survivor shall be responsible and liable for all the
liabilities and obligations of each of the Constituent Companies; and any claim
existing or action or proceeding pending by or against either of the
Constituent Companies may be prosecuted to judgment as if the merger had not
taken place, or Survivor may be substituted in its place and neither the rights
of creditors nor any liens upon the property of either of the Constituent
Companies shall be impaired by the merger. Survivor shall execute and deliver
any and all documents which may be required for it to assume or otherwise
comply with outstanding obligations of Absorbed.

Section 4. The manner and basis of converting the outstanding shares of the capital stock
of the Constituent Companies is as follows:

	 	a.	 	Each share of capital stock of Absorbed issued and outstanding
at the Effective Date of the merger shall be cancelled and no consideration
shall be issued or paid with respect thereto.
	 
	 	b.	 	The shares of capital stock of Survivor that are issued and
outstanding immediately prior to the Effective Date of the merger shall remain
issued and outstanding and shall be unaffected by the merger.

Section 5. Survivor shall pay all expenses of accomplishing the merger.

Section 6. If at any time Survivor shall consider or be advised that any further assignment
or assurances in law are necessary or desirable to vest or to perfect or confirm of record
in Survivor the title to any property or rights of Absorbed, or to otherwise carry out the
provisions hereof, the Board of Directors of Absorbed as of the Effective Date of the merger
shall execute and deliver any and all proper deeds, assignments and assurances in law, and
do all things necessary or proper to vest, perfect or confirm title to such property or
rights of Survivor.

Section 7. Each of the Constituent Companies shall take, or cause to be taken, all actions
or do or cause to be done, all things necessary, proper or advisable under the laws of the
State of Delaware, to consummate and make effective the merger, subject, however, to the
appropriate vote or consent of the shareholders of each of the Constituent Companies in
accordance with the requirements of the applicable provisions of the laws of the State of
Delaware.

 

 

Section 8. The Effective Date and time of the merger shall be specified in the Certificate
of Merger filed with the Delaware Secretary of State (the “Effective Date”), provided that
upon such date, all acts and things shall have been done as shall be required for
accomplishing the merger under the applicable provisions of the laws of the State of
Delaware.

Section 9. Anything herein or elsewhere to the contrary notwithstanding, this Agreement and
Plan of Merger may be abandoned by actions of the Board of Directors of the Constituent
Companies at any time prior to the Effective Date specified in Section 8 above of this
Agreement and Plan of Merger.

Section 10. This Agreement and Plan of merger shall be governed by and construed in
accordance with the laws of the State of Delaware, without regard to principles of conflict
of laws.

Signature page follows

 

 

     This Agreement and Plan of Merger may be executed in any number of counterparts, each of
which shall be an original document and which, when taken together, shall constitute one and the
same document.

	 	 	 	 	 
	 	BANC OF AMERICA SECURITIES HOLDINGS

CORPORATION

 	 
	 	By:  	/s/ ROBERT QUTUB
 	 
	 	 	Robert Qutub 	 
	 	 	President 	 
	 
	 	MERRILL LYNCH & CO., INC.

 	 
	 	By:  	/s/ THOMAS KELL MONTAG
 	 
	 	 	Thomas Kell Montag 	 
	 	 	President & Chief Executive OfficerExhibit 10.52

EXHIBIT 10.52

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

DISTRIBUTION SERVICES AGREEMENT

THIS DISTRIBUTION SERVICES AGREEMENT (this “Agreement”) is entered into and effective as of
January 1, 2010 (the “Effective Date”) by and between QLT Ophthalmics, Inc., having its principal
place of business at 1098 Hamilton Court, Menlo Park, California, 94025 ( “QLT”) and ASD Specialty
Healthcare, Inc. d/b/a Besse Medical having its principal place of business at 9075 Centre Pointe
Drive, Suite 140, West Chester, Ohio 45069 (“Distributor”).

WHEREAS, QLT commencing upon the Effective Date will market and sell QLT Inc.’s proprietary
product, Visudyne® (verteporfin for injection) (the “Product”), and infusion kits and patient
starter kits for use with the Product (collectively and individually, the “Kits”) in the United
States;

WHEREAS, QLT desires to appoint Distributor to distribute the Product and Kits in the United
States and provide additional services to QLT as set forth herein, on the terms and conditions in
this Agreement; and

WHEREAS, Distributor is willing to distribute the Product and Kits in the United States and
provide the additional services to QLT, on the terms and conditions hereinafter set forth;

NOW THEREFORE, in consideration of the mutual covenants contained herein, the parties agree as
follows:

Section 1 Definitions.

1.1 “Approved Customer” shall mean an entity that fits one of the categories set forth in
section 1.6 below, is approved by QLT in writing to receive the Product and/or Kits or has
purchased the Products and/or Kits from Distributor in the past.

1.2 “Non-Federal Contract Price Customer” shall mean an Approved Customer entitled to a
Contract Price.

1.3 “Federal Contract Price Customer” shall mean an Approved Customer entitled to the
applicable VA, Public Health Services or other federal prices as specified by QLT.

1.4 “Chargeback” means the amount submitted by Distributor to QLT via a manual process in an
Microsoft Excel spreadsheet (“EXCEL”) as an invoice claim that represents the difference between
the [*] and the applicable Contract Price for Products purchased by Approved Customers pursuant to
this Agreement.

1.5 “Contract Price” means the Product price to which a particular Non-Federal Contract Price
Customer is entitled, calculated by applying the applicable Discount Percent against the Ex-Factory
Price for a customer’s purchases, or for Federal Contract Price Customers, the pricing to which
such customer is entitled under Federal law as specified by QLT from time to time.

1.6 “Customer” means (a) an individual medical practitioner or a group of medical
practitioners that provide(s) ophthalmic health care services to patients in a medical practice and
who are: (i) ophthalmic medical professionals, such as Ophthalmologists or Optometrists, (ii)
licensed by and provide medical services in accordance with the laws of the State(s) within which
they operate, and (iii) employees or owners in part or in whole of the medical practice at which
they provide healthcare services to patients; (b) ambulatory eye surgery centers, (c) hospitals,
either public or privately owned, (d) federal hospitals and clinics, or (e) pre-approved specialty
pharmacies such as [*] or any other [*] which are approved by QLT in writing during the term of
this Agreement.

 

 

 

1.7 “Discount Percent” means the percentage set forth in Exhibit D by QLT that is used by
Distributor to reduce the Product’s Ex-Factory Price in determining the Contract Price for
Non-Federal Price Customers.

1.8 “Effective Date” shall have the meaning set forth in the preamble of this Agreement.

1.9 “Ex-Factory Price” shall mean the QLT published list price for a Product, excluding
payment terms and freight charges, that is charged to purchasing wholesalers and distributors. The
Ex-Factory Price is subject to change by QLT without notice.

1.10 “Kit” shall have the meaning set forth in the first whereas clause of this Agreement.

1.11 “Product” shall have the meaning set forth in the first whereas clause of this Agreement.

1.12 “United States” shall mean the United States of America, its territories and
possessions.

Section 2 Appointment and Acceptance.

2.1 Subject to the terms and conditions of this Agreement, QLT hereby appoints Distributor as
a distributor of Products and Kits in the United States, and an authorized distributor of record,
of the Product and the Kits in the United States to Approved Customers. Distributor will not be
[*] with respect to [*]. QLT shall comply with all applicable federal and state laws, including
any requirements to publicly disclose or make publicly available upon request the identity of its
authorized distributors.

2.2 Distributor accepts such an appointment and agrees to perform, and carry out its duties
and obligations under this Agreement.

2.3 [*] shall be responsible for all Chargebacks and returns of Product arising from sales to
Non-Federal or Federal Contract Price Customers in accordance with Sections 4.6 and 9, [*] pursuant
to the [*] Agreement by and between [*] and Distributor effective [*] (the “[*] Agreement”). Any
such Chargebacks and returns for [*] must occur within [*] after [*]. However, except as expressly
provided in this Section 2.3, any [*] shall be handled in accordance with the [*] Agreement, and
QLT shall [*].

Section 3 Duties of Distributor

3.1 Distributor will provide adequate personnel, automation, telecommunications and all other
materials and supplies needed to distribute the Product and Kits to Approved Customers in the
United States, carry out its duties under this Section 3, provide the additional services to QLT
set forth in Section 5 “Additional Services” herein, and to otherwise meet its obligations under
this Agreement, including but not limited to the application of the correct Contract Price to each
Approved Customer. Distributor will ensure that the personnel handling Product and Kits,
interacting with Customers, and performing any other activities hereunder, are properly trained to
perform their respective functions.

3.2 Distributor will make all final decisions on staffing relating to carrying out its duties
and responsibilities under this Agreement. Distributor will review staffing levels on a continuous
basis with QLT and upon request, will provide relevant data and staffing formula used in
determining staffing including, but not limited to, transactions per person, average number of
calls, call length, and other formula or standards used to assign staff. Distributor will provide
adequate back-up personnel and floaters during anticipated peak demand and/or vacations.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

2

 

3.3 Distributor will appoint an individual who will serve as the manager of the relationship
with QLT and will have overall managerial responsibility for the implementation of this Agreement
(“Visudyne Program Manager”). The Distributor’s Visudyne Program Manager shall be [*]. QLT’s
primary contact to Distributor for this Agreement shall be [*]. The parties shall notify each
other of changes in such Visudyne Program Manager and primary contact person pursuant to Section 23
“Notices” hereof.

3.4 Distributor will at all times handle, store and distribute the inventory of the Product
and Kits in accordance with the specifications for storage and handling of the Product and Kits
provided to Distributor by QLT in writing, and any deviations from such specifications should be
reported to QLT immediately. In handling storing, selling and distributing the Product and Kits
and otherwise fulfilling its obligations under this Agreement, Distributor shall comply with all
applicable federal, state and local laws, regulations and ordinances, including but not limited to
the Prescription Drug Marketing Act of 1987, as amended, any regulations promulgated thereunder and
any equivalent state laws and any laws and regulations relating to recall and the disposal of
hazardous wastes. At QLT’s request, Distributor shall provide QLT with evidence of its compliance
with laws, including but not limited to copies of state licenses, permits and, if legally
permitted, governmental inspection reports for Distributor’s facilities. Distributor shall notify
QLT immediately in the event of (a) any breach by Distributor of its obligations under this Section
and/or (b) any notices, requests for information or other communications from the U.S. Department
of Health and Human Services or any other government agency or any state healthcare program or
other state agency (“Government Agency”) alleging that Distributor has violated any of the
requirements of this Section and, if allowed by law, will give QLT copies of any such
communications. To the extent not prohibited by law, Distributor shall meaningfully discuss with
QLT any corrective actions to be implemented by Distributor and shall enable representatives of QLT
to participate in (including without limitation by providing reasonable advance notice of ) any
communications or meetings on this subject with any Government Agency.

3.5 Distributor will place orders with QLT using purchase orders issued via fax or e-mail
transmissions. Distributor shall communicate inventory levels via the standard EXCEL spreadsheet
submission.

3.6 Distributor will provide QLT with its documented process (i.e., by flow chart or Standard
Operating Procedure (“SOP”) for involving the contracted reimbursement specialist for the Product.

3.7 Distributor’s Visudyne Program Manager and other Distributor representatives shall meet at
least once every calendar quarter with QLT representatives on a mutually agreed upon schedule to
review the service levels, savings potential, process improvements, and operations conducted under
this Agreement.

3.8 Distributor will maintain the customer service levels set forth in Exhibit A attached
hereto and made a part hereof.

3.9 It is understood that Distributor sells and distributes other ophthalmic products. 
Nothing in this Agreement shall prevent Distributor from listing such other products for sale (and
their associated pricing) in its print materials, catalogs, web site, and other communication
materials.  Furthermore, nothing herein shall prevent Distributor or its affiliates from filling
orders for another ophthalmic product by or for Customers, or from promoting its distribution
services generally in accordance with its standard business practices, which typically includes
informing its purchasers of pricing available for all of the products distributed by Distributor.
Notwithstanding the foregoing, Distributor shall not [*] or that [*] or that [*].

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

3

 

3.10 [Intentionally deleted]

3.11 [Intentionally deleted]

3.12 Distributor shall refer Approved Customers and potential Approved Customers to QLT’s
Customer Interactive Center for inquiries for medical and educational inquiries with respect to the
Product and the use of the Product.

3.13 Distributor shall maintain an inventory of the Product and the Kits which is adequate to
supply the Product and Kits to the Customers.

3.14 Distributor shall promptly, no later than by the close of the following business day,
report to QLT’s safety unit at 1-800-663-5486, any and all Visudyne-related adverse events, and to
QLT’s quality assurance unit, any and all technical or Visudyne-related product complaints, which
it receives relating to the Product or Kits in order to permit QLT to comply with regulatory
requirements; provided any adverse medical events involving death or major injury shall be reported
immediately.

3.15 Distributor shall not distribute or generate any promotional material containing claims
relating to the Product or Kits. Distributor may, however, with QLT’s consent, provide Approved
Customers with educational information concerning the Product, provided that any such educational
information has been approved in advance in writing by QLT and has been provided for that purpose
by QLT.

3.16 Distributor will cooperate with and assist QLT in the event of any recall or governmental
investigation of the Product or Kits. In connection therewith, Distributor will process recalls,
[*], in accordance with all applicable laws, rules and regulations, and any other standards agreed
to by the parties, for Product distributed by Distributor.

Section 4 Pricing & Purchasing/Adding & Deleting Approved Customers/Chargeback Process

4.1 Applicable Contract Prices. Distributor is responsible for ensuring that Approved
Customers receive the correct price for Product as set forth below in Section 4.2.

4.1.1 Approved Customers who are not Non-Federal or Federal Contract Price Customers may
purchase Product at no more than the prevailing QLT Ex-Factory Price as set forth in Exhibit D.
Such customer may include specialty pharmacies and other entities approved by QLT from time to
time. The Ex-Factory Price is subject to change without notice.

4.1.2 Federal Contract Price Customers shall [*]. QLT shall give Distributor timely [*] on a
quarterly basis.

4.1.3 Non-Federal Contract Price Customers, such as ophthalmologists, clinics and hospitals as
approved by QLT from time to time, shall receive pricing at [*] the Contract Prices referenced in
Exhibit D.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

4

 

4.2 Contract Price Effective Dates and Change without Notice. Contract Prices for Non- Federal
Contract Price Customers are effective no later than [*] and shall be subject to change without
notice as Ex-Factory Prices change. Contract Prices are equal to the Ex-Factory Price in effect at
the time of an Approved Customer’s purchase and will be reduced by an amount equal to the Discount
Percent in effect at the time of purchase multiplied by the Ex-Factory Price then in effect.

4.3 Contract Prices Creating a New “Best Price”. If any price or other benefit offered to a
Non-Federal Contract Price Customer under the terms of this Agreement, alone or in combination with
any other pricing arrangement affecting an Approved Customer, would result in a Product “Best
Price” as the term is used in 42 U.S.C. §1396r-8(c) (1) (C), then such price or benefit to an
Approved Customer shall [*] to the extent necessary so that [*]. If QLT notifies Distributor of
[*], then Distributor may, within sixty (60) days of receipt of such notice, [*] by written notice
to QLT.

4.4 Price Commitments. QLT takes exception to and rejects any provision in any document
furnished to QLT by Distributor which in any way requires QLT to make available to Distributor or
an Approved Customer [*] available to any other customer or customer segment or group. Moreover,
QLT takes exception to and rejects any purported requirement in any document furnished to QLT by
Distributor that [*] therefor offered under this Agreement.

4.5 Purchase Through Distributor. All purchases made by an Approved Customer shall be through
Distributor. Distributor represents that it has the capability to transmit Chargebacks to QLT
through a manual process using an Excel spreadsheet (“Excel”). Distributor acknowledges that its
Approved Customers will agree (without any involvement of QLT) with Distributor on the final price
for Products, including the consideration to be received by Distributor in exchange for its
performance of the wholesaler function.

4.6 Chargeback Reconciliation. Sales to Non-Federal or Federal Contract Price Customers shall
be handled via QLT’s normal Chargeback procedures. Distributor will submit all Chargeback claims,
which shall be equal to [*]. Such submission shall be made on a [*] basis using an invoice in the
form of an Excel spreadsheet, the form and content of which is acceptable to both parties. QLT
will make a good faith effort to use the Chargeback data submitted by Distributor to match the
Chargeback for the Products to this Agreement (or, to the extent that Section 2.3 applies, the [*]
Agreement) such that Non-Federal and Federal Contract Price Customers receive the Contract Price
set forth in this Agreement. Due to the quality of data received and the limitations inherent in
QLT’s systems, however, QLT cannot guarantee that all such Chargeback information will be applied
against this Agreement. Without limiting the foregoing, in the event that [*], including but not
limited to this Agreement. If [*] within the database [*]. If a [*] the Chargeback will be
processed [*]. If QLT’s system [*]. Once QLT has [*], QLT will not [*]; provided however, that
Distributor may resubmit disputed Chargeback to QLT within [*] of receiving QLT’s reconciliation
notice, and QLT shall process any resubmitted Chargebacks within such [*] time period, provided
that Distributor can substantiate its claim for resubmission. QLT shall pay all submitted
Chargebacks that are applied against this Agreement as provided in this Section 4.6 within [*]
after it receives the relevant invoice therefor.

4.7 “Own Use” Requirements. QLT shall extend the pricing offered in this Agreement to Federal
and Non-Federal Contracted Customers pursuant to this Agreement only if Distributor notifies each
such Customer that it must meet the following condition:

4.7.1 All Products purchased pursuant to this Agreement shall be for any Approved Customer’s
“own use,” as that phrase is defined in Abbott Laboratories v. Portland Retail Druggists, 425 U.S.
1 (1976), in supplying the pharmaceutical needs of patients at Customers’ facilities eligible for
Contract Prices pursuant to this Agreement, in combination with other health care services.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

5

 

4.8 Approved Customers. QLT must approve, in its reasonable discretion, any customers who are
not already Approved Customers as of the Effective Date accessing the Product or, if applicable,
Contract Prices, pursuant to this Agreement after Distributor submits the information listed on
Exhibit F attached hereto and as reasonably requested by QLT. No approval will be given for
entities that are not so approved or do not meet the requirements of this Section 4.8 or other
applicable requirements of this Agreement. Where applicable, QLT shall use [*], in assisting it to
determine whether or not a Customer meets the requirements of this Agreement. No entity shall be
added as an Approved Customer unless and until QLT so notifies Distributor. QLT may revoke its
acceptance of any Customer by notifying Distributor. If QLT approves the addition of a Customer,
any Contract Price for such new Approved Customer will become effective no later than [*] after
receipt of Distributor’s written notification. Further, QLT reserves the right at any point during
the term of the Agreement to revoke Distributor’s access to Approved Customers that do not meet the
requirements of this Agreement, or for any commercially reasonable reason, [*].

4.9 Participant Location. The benefits of this Agreement, including access to Product and, if
applicable, Contract Prices, shall be available only to Approved Customers, or Approved Customer
facilities as the case may be, located in the United States. In addition, QLT may, in its sole
discretion, [*] in a manner [*]. Moreover, in the event that [*] described in this Agreement
(including but not limited to, [*], QLT may [*] or otherwise affected by [*].

4.10 QLT Contracts with Non-Federal Contract Price Customers. QLT takes exception to and
rejects any purported requirement in any document furnished to QLT by Distributor that a direct
contract between QLT and a Customer or other buying group member Customers must be previously
approved by Distributor. Any such contract shall be between QLT and the buying group member only
and does not affect any of the terms and conditions of this Agreement.

4.11 Patient Assistance Program. In addition to the distribution and other services described
in this Agreement, Distributor agrees to distribute the Product associated with patients enrolled
in QLT’s patient assistance program (“PAP”). QLT administers the PAP through a third party service
provider, as identified by QLT from time to time (the “PAP Provider”). Upon notification from the
PAP Provider, Distributor agrees to promptly ship the Product to medical practitioners for use with
PAP patients in accordance with the instructions received from the PAP Provider [*].
Notwithstanding Section 4.8, the practitioner receiving the Product pursuant to the PAP shall be
considered an “Approved Customer” hereunder solely for purposes of the PAP, [*]. Following
distribution of the Product, Distributor shall report to QLT the amount of such Product distributed
to practitioners for PAP patients and QLT shall then ship replacement Product to Distributor [*] to
replace the Product distributed to practitioners for PAP patients.

Section 5. Additional Services; Service Fees

5.1 Additional Services. In addition to its normal distribution duties under this Agreement,
Distributor will provide the following additional services to QLT in connection with the
distribution of the Product and Kits:

5.1.1 Distributor will enter into such agreements which will allow it to accept credit card
purchases from Customers, subject to credit approval of such Customers by Distributor. The fees
[*]. Distributor shall retain documentation of [*].

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

6

 

5.1.2 Distributor shall provide the specific data and reports set forth on Exhibit B attached
to this Agreement and made a part hereof, in the manner and frequency set forth in Exhibit B. The
fee for such data and reporting services shall be [*]. It is agreed and understood that if [*] in
all material respects within [*] unless [*].

5.1.3 Distributor shall ship all Product and Kits by a nationally recognized next day air
carrier. QLT shall [*] as demonstrated by [*].

5.1.4 The fee paid to Distributor by QLT for [*]. The services provided by Distributor will
include [*].

5.1.5 QLT shall pay the [*] amounts set forth in this Section 5 with respect to Product
shipped under QLT’s PAP pursuant to Section 4.11 of this Agreement to the same extent QLT pays the
[*] amounts with respect to Product sold to Approved Customers. In addition, QLT shall pay
Distributor a [*] Ex-Factory Price [*]. The services provided by Distributor with respect to QLT’s
PAP shall include [*], beginning after QLT’s first shipment of replacement Product pursuant to
Section 4.11 of this Agreement.

5.1.6 QLT and Distributor each believe that the [*] described in this Agreement constitute [*]
under this Agreement, and that [*] were negotiated in good faith and at arms’ length. Distributor
agrees that it [*], in whole or part, to any Approved Customers.

5.2 Invoicing and Terms of Payment. Distributor shall invoice QLT within [*] of the end [*]
for the fees and actual reimbursable costs associated with the [*] set forth in this Section 5.
Payment of undisputed amounts shall be due within [*] of receipt of the invoice. QLT will notify
Distributor of any disputed charges in writing within [*] of receipt of the invoice covering such
charges. In the absence of any such notice of dispute, all invoices will be deemed to be correct
and due in full per the payment terms above. A late fee of [*] (or any portion thereof) will be
charged as of the due date on all amounts not paid after [*] receipt of the invoice, except any
amount disputed by QLT in good faith.

5.3 [*]. If in any [*] Distributor can reasonably demonstrate to QLT that Distributor’s [*]
providing the services described in this Section 5 [*] during the following [*] of the Term (as
such term is defined in Section 21 below)) as a result of any [*], then Distributor may propose in
writing to QLT [*]. If Distributor so notifies QLT of any [*] the parties shall discuss [*]. No
such [*] unless and until [*]. If the parties do not agree upon [*], then either party may
terminate this Agreement in accordance with Section 21. In addition, the [*] as [*].
Notwithstanding the foregoing, in no event shall the [*]. All [*] will be determined [*].

Section 6 Price and Payment.

6.1 Price of Product and the Kits to Distributor shall be the Ex-Factory Price prevailing at
the time of purchase by Distributor. The Ex-Factory Price may change without notice. If the price
is [*], QLT agrees that it will [*] based on data [*] that Distributor must submit to QLT [*].
Credit will be issued within thirty (30) days of QLT’s receipt and acceptance of such report.
Prices are [*].

Section 7 Forecasts, Orders, Invoices.

7.1 Distributor will provide QLT with a non-binding [*] rolling forecast of projected
purchases of the Product and Kits on or before the [*] during the term of this Agreement.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

7

 

7.2 Distributor will provide QLT with purchase orders (“PO”) at least once every [*] and not
more than [*] in advance of the delivery date set forth on the PO. The PO will set forth the
quantity of Product and Kits and the requested delivery date. QLT will inform Distributor of any
problems with the PO within [*] of receipt.

7.3 QLT will invoice Distributor for the Product and Kits simultaneously with shipment
thereof. Payment shall be due within [*] of the date of the invoice and shall be payable by
electronic funds transfer. Distributor shall be entitled to a [*] if it pays within [*]. A late
fee of [*] (or any portion thereof) will be charged as of the due date on all amounts not paid
within [*] after receipt of the invoice.

Section 8. Delivery, Title and Risk of Loss, Damaged Shipments.

8.1 QLT will [*] on normal and customary orders shipped via regular methods directly to
Distributor’s designated warehouse. Notwithstanding the foregoing, where the Distributor [*], any
[*] will be charged to and borne by [*]. QLT agrees to ship all Products and Kits [*] to the
destination specified by Distributor from whichever warehouse is the shipping origin selected by
QLT. In all cases, title to Products and Kits purchased by Distributor and risk of loss and
damages to Products shipped by QLT will pass to Distributor upon [*]. Transfer by QLT [*] will
constitute full and complete performance by QLT of its obligations to ship Products and Kits to
Distributor.

8.2 [*] insurance for in transit damages to or losses of Products and Kits shipped hereunder
(each a “[*] Damage or Loss”). QLT will process and manage any claim. Insurance proceeds of [*]
Damage or Loss claims will be [*].

8.3 Distributor shall visually inspect each shipment of Product and Kits for external damage
or loss in transit and shall notify QLT in writing (or by e-mail or fax) of any shortage or other
non-conformity in any order delivery within five (5) business days of the delivery thereof
(“Discoverable Defects”). With respect to non-conformities of Product and Kits that by their
nature are not discoverable upon a reasonable visual inspection (“Hidden Defects”), the parties
agree that Distributor shall notify QLT promptly upon learning of or discovering a Hidden Defect.
Upon receipt of notice of any Discoverable Defect or Hidden Defect, QLT will at its option,
promptly at its sole expense either replace any Product or Kits with the Discoverable Defect or
Hidden Defect, or issue Distributor a credit in the amount of the purchase price paid for such
Product or Kit. THIS SETS FORTH QLT’S SOLE LIABILITY TO DISTRIBUTOR FOR PRODUCT WITH DISCOVERABLE
DEFECTS AND HIDDEN DEFECTS; PROVIDED THAT THE FOREGOING DOES NOT APPLY TO CLAIMS OF THIRD PARTIES
INVOLVING HIDDEN DEFECTS FOR WHICH INDEMNIFICATION OF DISTRIBUTOR IS APPLICABLE UNDER THIS
AGREEMENT OR THE CONTINUING GUARANTY (AS DEFINED BELOW).

Section 9 Returns.

9.1 All returns shall be subject to the QLT Returns Policy, Exhibit C, in effect at the time
of the return. The current QLT Returns Policy is attached hereto as Exhibit C and made a part
hereof. QLT reserves the right to change its returns policy on five (5) days prior written notice;
provided that such changes not apply to Products purchased prior to the effective date of change.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

8

 

Section 10 QLT Responsibilities.

QLT will supply the Product and Kits to Distributor under the terms and conditions of this
Agreement.

10.1 QLT will be responsible for the development and maintenance of the phone switch for
routing calls which come into QLT through an automated attendant to Distributor and the QLT
Customer Interaction Center.

10.2 In the event of a shortage of supply, QLT will [*] unless required by federal law or
regulation to [*]. Distributor will ensure that Customers are aware of any such shortage and the
guidelines Distributor has set up, in consultation with QLT, to allocate Product among patients
[*].

10.3 QLT will furnish Distributor with the Material Safety Data Sheet for the Product and any
revised versions thereof.

10.4 If the Product or Kit is discontinued, Distributor’s remaining inventory shall be [*].
QLT will not [*].

Section 11 Disclosures and Consents; HIPAA Compliance

11.1 To the extent required by applicable and regulations, including, but not limited to, 42
U.S.C. 1320a-7b(b) and 42 C.F.R. 1001.952(h), Distributor shall advise and inform each of its
Customers to fully report, as required by law or contract, any discounts, rebates, or reductions in
prices on Product and provide the discount information supplied by Distributor to the Department of
Health and Human Services or a state agency upon request, consistent with the requirements of 42
U.S.C. 1320a-7b(b) and 42 C.F.R. 1001.952(h).

11.2 Distributor represents and warrants that it shall comply in all respects with applicable
provisions promulgated by the U.S. Department of Health and Human Services pursuant to Title II,
Subtitle F of the Health Insurance Portability and Accountability Act of 1996, as amended (“HIPAA”)
including, but not limited to, standards for the protection of the privacy of individually
identifiable health information, as well as any other applicable law, regulation or contractual
obligation relating to privacy. At no time will Distributor provide to QLT, nor does QLT seek to
collect or receive, any protected health information (as such term is defined in HIPAA). The
provision of any information to QLT hereunder shall be in compliance with all applicable laws,
including those concerning patient confidentiality.

Section 12. Quality Audits.

12.1 Distributor will provide fully automated and manual quality control systems designed to
ensure compliance with applicable law. Such systems will be designed to verify the accuracy of
inventory and shipments to customers in order to effectively facilitate recall processing if
required. QLT is entitled to perform annual quality audits with Distributor to assure appropriate
storage conditions, accurate SOPs, customer shipping records, and adequate employee training
records are in place. Any quality audit hereunder shall be consistent with Section 13 hereof.

Section 13 Right to Audit.

13.1 Distributor will maintain detailed records, books and accounts related to its Customers
and activities under this Agreement. Distributor will permit QLT’s authorized agents or
representatives, during normal business hours at QLT’s expense, to inspect all such documents and
other relevant information regardless of its form in retention, including, but not limited to
computer files or tapes pertaining to this Agreement. QLT will provide Distributor at least seven
(7) days notice in advance of any audit. Any audit hereunder shall be consistent with this Section
13 hereof.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

9

 

13.2 Distributor will not dispose of any records related to this Agreement for a period of [*]
from date of creation of such record, or for such longer amount of time as may be required under
applicable law. On request, Distributor will transfer such records to QLT prior to disposal, at
QLT’s expense.

13.3 Distributor shall cooperate with QLT’s auditors to assure a prompt and accurate audit.
Distributor shall also cooperate in good faith with QLT to correct any practices which are found to
be deficient as a result of any such audit. Within thirty (30) days after receipt by Distributor
of QLT’s audit report containing findings of deficient practices which have caused or resulted in
excess fees paid to, or unauthorized or erroneous expenses incurred by, QLT, Distributor shall
reimburse QLT for any such excess fees, unauthorized or erroneous expenses within thirty (30) days
of provision of such audit findings to Distributor. If Distributor objects to the results of the
audit, the parties will work diligently to resolve any issues under this Section 13.3, including
raising such issues to the next level of management within Distributor and QLT for resolution.
Should the audit conducted by QLT result in a finding of underpayment by QLT to Distributor, QLT
shall, within thirty (30) days of provision of such audit finding to Distributor, remit to
Distributor all monies owed. If the parties cannot resolve such issues within sixty (60) days of
receipt of QLT’s audit report, the parties shall retain an independent certified public accountant,
to whom neither party has a reasonable objection, to audit Distributor’s records. The results of
such independent accountant’s audit shall be binding upon both parties. The Parties shall [*] of
such independent accountant [*].

13.4 In the event the deficiencies relate to compliance with applicable laws or regulations,
Distributor shall remedy such deficiencies as soon as possible.

13.5 The right to audit shall survive the expiration or termination of this Agreement by [*].

13.6 QLT reserves the right, with reasonable advance notification, to enter and inspect
Distributor’s returned goods facility or any Distributor’s authorized third party reverse
distributor no more than once annually. Distributor shall provide or ensure access to said
facilities. Such audit will be performed at the cost of QLT. Submission of returns to QLT shall be
deemed acceptance of the terms of QLT’s return policy. The audit will be conducted at QLT’s expense
only for the expenses incurred in the hiring of the third party designated by QLT. Other expenses,
including but not limited to, time spent by permanent or temporary employees of Distributor in the
support of the audit will not be reimbursed by QLT.

Section 14 Confidentiality.

14.1 QLT (as successor and assignee of QLT Inc.) and Distributor are parties to a Mutual
Non-Disclosure Agreement dated as of November 2, 2009 (the “NDA”). The terms of the NDA are
incorporated herein by reference; provided that Section 9 of the NDA (Term) is hereby revised so as
to cover Confidential Information that is disclosed during the Term of this Agreement, and the
obligations created in the NDA shall survive and continue to be binding on the parties for five (5)
years from the date of termination of this Agreement. QLT shall be permitted to disclose
Confidential Information to the extent required under applicable laws, rules, regulations,
including relating to securities and regulatory requirements in accordance with Section 8 of the
NDA, provided that notwithstanding the foregoing, the parties acknowledge and agree that QLT may be
required to file this Agreement with the U.S. Securities and Exchange Commission and its foreign
equivalents (“SEC”) and/or make other public disclosures regarding this Agreement in its filings
with the SEC in order to comply with applicable securities laws, in which case QLT shall be
permitted to do so, provided that QLT shall seek, to the extent consistent with applicable laws, to
obtain confidential treatment of, and redact from any version of this Agreement so filed with the
SEC, all references to specific service fee amounts and discounts in this Agreement, and further
provided that if QLT, in consultation with its legal counsel, reasonably believes that such service
fee amounts and discounts are legally required to be disclosed, or the SEC or equivalent government
authority requires disclosure of such amounts and discounts, then QLT shall notify Distributor in
writing of such requirement and the basis therefor a reasonable time before such disclosure is
legally required to be made, and shall be permitted to disclose such amounts and discounts when
making such filings after such time.

14.2 Distributor will not report [*].

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

10

 

Section 15 Representations, Warranties and Covenants.

15.1 Distributor represents and warrants that:

15.1.1 it has and will maintain in full force and effect all governmental licenses and permits
to sell and distribute the Products and Kits in the United States and to conduct all other
activities it is required to perform under this Agreement, and shall immediately notify QLT of any
denial, revocation or suspension of any such licenses or permits that could reasonably have a
material adverse effect on the Product or Kits, or Distributor’s ability to perform its obligations
under this Agreement;

15.1.2 the services provided by Distributor hereunder will be performed in a good,
professional and workmanlike manner, and Distributor shall ensure that its personnel adhere to the
provisions of this Agreement and that they have the requisite knowledge training and ability to
perform such Services under this Agreement competently and in accordance with the terms hereof;

15.1.3 In performing services pursuant to this Agreement, Distributor and its employees and
agents shall comply with all federal, state and local laws, rules, regulations and ordinances;

15.1.4 Distributor has the full right and authority to enter into this Agreement and
Distributor has no obligations or commitments inconsistent with this Agreement and/or its
performance hereunder;

15.1.5 The execution, delivery and performance of this Agreement by Distributor has been duly
authorized by all necessary corporate actions; and

15.1.6 No Distributor employee or subcontractor shall be, and Distributor has not been,
debarred under 21 U.S.C. §335a or convicted of a felony relating to the regulation, handling or
storage of any drug product, and Distributor shall promptly notify QLT in writing if Distributor or
any Distributor employee or subcontractor (a) to Distributor’s knowledge comes under investigation
by FDA for debarment or disqualification, (b) is debarred or disqualified by the FDA, (c), to
Distributor’s knowledge comes under investigation by any federal, state, municipal or other law
enforcement agency in connection with the regulation or handling of any drug product, or (d) is
convicted of a felony relating to the regulation or handling of any drug product, in each of (a)
through (d) where such event could trigger an obligation by QLT to file a report or other document
with the FDA or reasonably have a material adverse effect on the Product or Kits or Distributor’s
ability to perform its obligations under this Agreement.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

11

 

15.2 QLT represents and warrants that:

15.2.1 QLT or its affiliates owns or holds the duly approved New Drug Application, as such
term is defined in the Federal Food, Drug and Cosmetic Act, Title 21, United States Code, as
amended, and the rules and regulations promulgated thereunder, for the Product, or is otherwise
considered the “manufacturer” of the Product within the meaning of any applicable federal, state or
local law relating to pedigrees;

15.2.2 QLT has and will maintain, in full force and effect, all licenses and permits required
under applicable federal, state or local law for QLT to sell and distribute Products in the United
States under this Agreement;

15.2.3 In performing its obligations pursuant to this Agreement, QLT and its employees and
agents shall comply with all federal, state and local laws, rules, regulations and ordinances;

15.2.4 QLT has the full right and authority to enter into this Agreement and QLT has no
obligations or commitments inconsistent with this Agreement and/or its performance hereunder;

15.2.5 The execution, delivery and performance of this Agreement by QLT has been duly
authorized by all necessary corporate actions; and

15.2.6 QLT will convey to Distributor good title to the Product and Kits, free and clear of
any security interest, liens or other encumbrances of any kind or character.

15.2.7 EXCEPT AS PROVIDED ABOVE OR IN THE CONTINUING GUARANTY (AS DEFINED BELOW), QLT
DISCLAIMS ALL OTHER WARRANTIES, WHETHER EXPRESS OR IMPLIED, WITH REGARD TO THE PRODUCT PURCHASED BY
DISTRIBUTOR PURSUANT TO THIS AGREEMENT, INCLUDING THE WARRANTY OF MERCHANTABILITY AND THE WARRANTY
OF FITNESS FOR A PARTICULAR PURPOSE.

15.3 QLT has, on the Effective Date, executed and delivered to Distributor’s parent the
Continuing Guaranty and Indemnification Agreement attached hereto as Exhibit E (the “Continuing
Guaranty”). The representations, warranties and indemnification provisions contained in the
Continuing Guaranty are in addition to those contained in this Agreement. QLT acknowledges that
the Products are covered by the Continuing Guaranty, and QLT shall perform its obligations set
forth in the Continuing Guaranty.

Section 16 Compliance with Law.

16.1 Each party will comply with all applicable laws and regulations relating to its
obligations under this Agreement. Each party will comply with all applicable provisions of the
federal anti-kickback statute, 42 U.S.C. §1320a-7b and all applicable related regulations and
similar state laws, including those laws and regulations related to federal healthcare programs,
including Medicare. Without limiting the foregoing, each party warrants that it will comply all
applicable disclosure requirements in connection with pricing, or any other applicable matters
under this Agreement.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

12

 

Section 17 Financial Disclosure.

17.1 QLT acknowledges that Distributor is a subsidiary of a publicly owned company whose
financial statements are a matter of public record on file with the Securities and Exchange
Commission, and that as long as Distributor remains a subsidiary of a publicly owned company, QLT
will first obtain the publicly available financial statements prior to requesting any such
financial statements or any other financial information from Distributor.  If Distributor is no
longer a subsidiary of a publicly owned company or such company’s financial statements are not a
matter of public record on file with the Securities and Exchange Commission, Distributor agrees to
provide QLT with audited annual financial statements and quarterly updates.

Section 18. Indemnification and Insurance.

18.1 By QLT. QLT shall defend, indemnify, and hold harmless Distributor and its affiliates,
directors, officers, employees and representatives from any claims, demands, costs, expenses
(including reasonable attorneys’ fees) and liabilities or losses (“Claims”) that may be asserted
against Distributor or such person or entity by or on behalf of a third party to the extent that
such Claims result from or arise out of the negligence or willful misconduct of QLT in connection
with its manufacture or sale of the Product or QLT’s breach of this Agreement or applicable laws,
rules and regulations.

18.2 By Distributor. Distributor shall defend indemnify and hold harmless QLT and its
affiliates, directors, officers, employees and representatives from any Claims that may be asserted
against QLT or such person or entity by or on behalf of a third party to the extent that such
Claims result from or arise out of the negligence or willful misconduct of Distributor in
connection with its sale and distribution of the Products or Distributor’s breach of this Agreement
or applicable laws, rules or regulations.

18.3 Indemnification Procedures. The obligations and liabilities of the parties with respect
to claims subject to indemnification under this Agreement (“Indemnified Claims”) are subject to the
following terms and conditions:

18.3.1 The party claiming a right to indemnification hereunder (“Indemnified Person”) will
give prompt written notice to the indemnifying party (“Indemnifying Person”) of any Indemnified
Claim, stating its nature, basis and amount, to the extent known. Each such notice will be
accompanied by copies of all relevant documentation, including any summons, complaint or other
pleading that may have been served or any written demand or other document.

18.3.2 With respect to any Indemnified Claim: (a) the Indemnifying Person will defend or
settle the Indemnified Claim, subject to provisions of this subsection, (b) the Indemnified Person
will, at the Indemnifying Person’s sole cost and expense, cooperate in the defense by providing
access to witnesses and evidence available to it, (c) the Indemnified Person will have the right to
participate in any defense to the extent that, in its judgment, the Indemnified Person may
otherwise be prejudiced thereby (with the Indemnified Person paying for such participation except
where counsel engaged by the Indemnifying Person could reasonably be deemed to have a conflict of
interest in representing the Indemnified Person, in which case the Indemnifying Person shall pay
all costs of such participation), (d) the Indemnified Person will not settle, offer to settle or
admit liability as to any Indemnified Claim without the written consent of the Indemnifying Person,
and (e) the Indemnifying Person will not settle, offer to settle or admit liability as to any
Indemnified Claim in which it controls the defense if such settlement, offer or admission contains
any admission of fault or guilt on the part of the Indemnified Person, or would impose any
liability or other restriction or encumbrance on the Indemnified Person, without the written
consent of the Indemnified Person.

18.3.3 Each party will cooperate with, and comply with all reasonable requests of, each other
party and act in a reasonable and good faith manner to minimize the scope of any Indemnified Claim.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

13

 

18.3.3 Distributor agrees that it will maintain, during the Term, insurance [*], including but
not limited to general liability insurance and workers’ compensation insurance. Upon reasonable
request, Distributor will promptly submit evidence of Distributor’s insurance to QLT.

18.4 QLT agrees that it will maintain the insurance set forth in the Continuing Guaranty.

Section 19 Use of Names.

19.1 Both parties reserve the right to control the use of their own names, trademarks, service
marks, symbols, or trade names. Except as provided by law or as required by this Agreement,
neither party may advertise or use any of the other party’s trademarks, service marks, symbols, or
trade names other than for the purpose of describing the Product in Distributor’s advertising or
promotional materials, without first receiving the prior written consent of the other party.
Distributor shall not issue any press release concerning the Agreement or its relationship with QLT
without the prior written approval of QLT.

Section 20 Liability; Force Majeure.

20.1 NO PARTY WILL BE LIABLE TO ANY OTHER PARTY FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT,
SPECIAL, PUNITIVE, OR OTHER SIMILAR DAMAGES (INCLUDING WITHOUT LIMITATION, LOST PROFITS) ARISING
OUT OF OR IN CONNECTION WITH A BREACH OF THIS AGREEMENT EVEN IF SUCH DAMAGES ARE REASONABLY
FORESEEABLE; PROVIDED THAT THE FOREGOING DOES NOT APPLY TO CLAIMS OF THIRD PARTIES FOR WHICH
INDEMNIFICATION OF DISTRIBUTOR IS APPLICABLE UNDER THIS AGREEMENT OR THE CONTINUING GUARANTY.

20.2 Neither party shall be responsible for any failure to comply with the terms of this
Agreement due to: fire; flood; hurricane, explosions; acts of God; labor strikes; inability of a
third party manufacturer to supply; acts of a government or agency thereof; judicial action; any
healthcare or pharmaceutical legislation which materially alters the commercial benefit of this
Agreement; or any other cause outside the reasonable control of a party (financial inability to pay
excepted). The party affected by a Force Majeure shall make diligent efforts to overcome such
event and resume performance under this Agreement.

Section 21 Term and Termination.

21.1 The term of this Agreement (“Term”) shall commence on the Effective Date, and shall
terminate on December 31, 2011, unless sooner terminated under the terms of this Agreement.
Thereafter, this Agreement shall automatically renew for subsequent terms of one additional year,
unless either party provides the other party with written notice of its intent not to renew this
Agreement at least 120 days before expiration of the current Term.

21.2 Either party may terminate this Agreement for cause, upon 30 days’ written notice of a
material default to the other party with a reason for termination, and failure of that party to
cure the default within the 30 day period. After the conclusion of the first year of the Term,
either party may terminate this Agreement at will upon at least 120 days’ prior written notice to
the other party.

21.3 Either party may terminate this Agreement immediately on written notice in the event the
other party becomes insolvent or files for bankruptcy or has filed against it any petition in
bankruptcy, has a receiver appointed for its business or property, or makes a general assignment
for the benefit of its creditors.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

14

 

21.4 Either party may immediately terminate this Agreement on written notice to the other
party in the event of a change in law that would make this Agreement unlawful. In addition, QLT, at
its sole election, may terminate this Agreement immediately, upon written notice to Distributor in
the event of (a) a withdrawal of the Product’s NDA; (b) a withdrawal of the Product from the market
for medical or scientific concerns as to toxicity, safety and/or efficacy; (c) a withdrawal of the
Product at the request of the FDA or any other governmental or regulatory agency or (d) any license
or registration required by Distributor under any federal, state or local law becoming suspended or
revoked that has a material adverse effect on Distributor’s ability to perform its obligations
under this Agreement.

21.5 The rights and obligations of the parties contained in Sections 9, 13, 14, 15 (solely as
to activities conducted during the Term), 18, 20 this Section 21.5 and Sections 11.1 and 11.2 and
22 through 25 of this Agreement, any payment obligations, and any other provision if its context
shows that the parties intend it to survive, will survive expiration or termination of this
Agreement and, except as expressly provided, expiration or termination will not affect any
obligations arising prior to the expiration or termination date.

21.5.1 If this Agreement is terminated (i) by Distributor following an uncured material breach
by QLT or (ii) by QLT at will, then at Distributor’s option exercised in writing within [*] after a
party receives notice of such termination from the terminating party, QLT shall promptly [*], at
[*]. Within [*] after Distributor provides or receives notice of such termination of this
Agreement, Distributor shall [*] at the time of termination.

21.5.2 If this Agreement is terminated (i) by QLT following a breach by Distributor or (ii) by
Distributor without cause, then at QLT’s option exercised in writing within [*] after a party
receives notice of such termination from the terminating party, QLT may promptly [*], at [*].
Within [*] after Distributor provides or receives notice of such termination of this Agreement,
Distributor shall [*] at the time of termination to enable QLT to determine whether to exercise the
foregoing option.

21.6 Upon termination or expiration of this Agreement, Distributor shall immediately cease to
represent itself as an authorized distributor with respect to the Product and Kits; provided,
however, that Distributor shall have the right to sell, during the [*] following such termination
or expiration only in accordance with the provisions of this Agreement, notwithstanding the
termination or expiration of this Agreement, those Products which are in its inventory on the date
of such termination and which QLT has not repurchased pursuant to the provisions of Section 21.5
hereof.

Section 22 Miscellaneous.

22.1 No waiver of any breach of any one or more of the conditions or covenants of this
Agreement by a party shall be deemed to imply or constitute a waiver of a breach of the same
condition or covenant in the future, or a waiver of a breach of any other condition or covenant of
this Agreement.

22.2 If any provision or the scope of any provision of this Agreement is found to be
unenforceable or too broad by judicial decree, the parties agree that such provisions shall be
curtailed only to the extent necessary to conform to law to permit enforcement of this Agreement to
its full extent.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

15

 

22.3 Each of the parties agrees and acknowledges that this Agreement, including the
attachments referred to herein and the NDA, (i) constitutes the entire agreement and supersedes all
prior and contemporaneous agreements, understandings, negotiations and discussions, whether oral or
written, among the parties with respect to the subject matter of this Agreement, and (ii) is not
intended to confer any rights or remedies, or impose any obligations, on any person other than the
parties hereto. Each of the parties expressly agrees and acknowledges that, other than those
statements expressly set forth in this Agreement, it is not relying on any statement, whether oral
or written, of any person or entity with respect to its entry into this Agreement or to the
consummation of the transactions contemplated by this Agreement, and each of the parties further
waives any claim against the other party that such other party has failed to disclose any fact,
occurrence or other matter that relates in any way to its entry into this Agreement.

22.4 This Agreement may be modified only by a written agreement signed by both parties.

22.5 This Agreement may be assigned by Distributor to any affiliate but may not be otherwise
assigned without the consent of QLT, which consent will not be unreasonably withheld. For purposes
of this Agreement, “affiliate” means any company or person that directly or indirectly controls, is
controlled by or is under common control with the referenced party, as the case may be. This
Agreement may be assigned by QLT without the consent of Distributor to an affiliate, to any entity
with whom it may merge or amalgamate or to any entity acquiring all or substantially all of the
assets of QLT to which this Agreement relates, but may not otherwise be assigned without the
consent of Distributor, which consent will not be unreasonably withheld. Any permitted assignee
shall assume all obligations of its assignor under this Agreement. No assignment shall relieve
either party of responsibility for the performance of any accrued obligations which such party then
has under this Agreement.

22.6 This Agreement and the rights and obligations of the parties under this Agreement will be
construed and interpreted under the internal laws of the State of California, excluding its
conflict and choice of law principles. Both parties hereby waive their right to a trial by jury
and, therefore, all disputes and conflicts regarding this Agreement and the parties’ performance
hereunder will be heard before a judge in a court of competent jurisdiction.

22.7 Distributor’s relationship with QLT hereunder shall be that of independent contractor,
and neither party shall be considered the agent of, partner of, employee or other member of the
workforce of, or participant in a joint venture with, the other party, in its performance of all
duties under this Agreement. Neither party shall have authority to bind the other party unless
otherwise agreed to in writing by such parties.

22.8 Each party to this Agreement (i) has participated in the preparation of this Agreement,
(ii) has read and understands this Agreement, and (iii) has been represented by counsel of its own
choice in the negotiation and preparation of this Agreement. Each party represents that this
Agreement is executed voluntarily and should not be construed against a party solely because it
drafted all or a portion of this Agreement.

22.9 This Agreement may be executed in multiple counterparts, each of which shall be deemed an
original but all of which together shall constitute one and the same instrument. Facsimile
execution and delivery of this Agreement are legal, valid and binding execution and delivery for
all purposes.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

16

 

Section 23 Notices. Any notice, request or other document to be given hereunder to a party shall
be effective when received and shall be given in writing and delivered in person or sent by
overnight courier or registered or certified mail, return receipt requested, as follows:

	 	 	 
	If to Distributor:

	 	Besse Medical
	 

	 	9075 Centre Pointe Drive
	 

	 	Suite 140
	 

	 	West Chester, Ohio 45069
	 

	 	Attention: VP Operations
	 
	 	 
	With a copy to:

	 	AmerisourceBergen Specialty Group, Inc.
	 

	 	3101 Gaylord Parkway
	 

	 	Frisco, TX 75034
	 

	 	Attention: Group Counsel, 1N-E186
	 
	 	 
	If to QLT:

	 	QLT Ophthalmics, Inc. 

1098 Hamilton Court
	 

	 	Menlo Park, CA 94025
	 

	 	Attention: President
	 

	 	Fax: [*]
	 
	 	 
	With a copy to:
	 	QLT Inc.
	 

	 	887 Great Northern Way, Suite 101
	 

	 	Vancouver, British Columbia
	 

	 	Canada V5T 4T5
	 

	 	Attention: Legal Department
	 

	 	Fax: [*]

or to such other address as either party may hereafter designate by notice to the other party. The
date of giving of any such notice shall be deemed to be five (5) days after mailing, or on the date
received, if by an express mail carrier.

Section 24 Status of Besse Medical. QLT acknowledges that (i) Besse Medical is a division and
fictitious name (d/b/a) of ASD Specialty Healthcare, Inc., and (ii) ASD Specialty Healthcare, Inc.
also does business under the names ASD Healthcare and Oncology Supply. It is the parties’
intention that the ASD Healthcare and Oncology Supply of ASD Specialty Healthcare, Inc. will not be
distributing Products and Kits. The signatory for Besse Medical below is an authorized signatory
for ASD Specialty Healthcare, Inc., doing business as Besse Medical.

IN WITNESS WHEREOF, and intending to be legally bound hereby, each of the parties executes
this Agreement of the Effective Date.

	 	 	 	 	 	 	 	 	 	 	 	 	 
	QLT OPHTHALMICS, INC.	 	ASD SPECIALTY HEALTHCARE, INC.	 	 
	 	 	 	 	 	 	D/B/A BESSE MEDICAL	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Alexander Lussow	 	By:	 	/s/ Michael E. Besse	 	 
	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	Alexander Lussow
	 	 	 	Name:
	 	Michael E. Besse	 	 
	 

	 	Title:
	 	President
	 	 	 	Title:
	 	President / G.M.	 	 

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

17

 

EXHIBIT A

Services Provided by Specialty Distributors

If the customer is under contract pricing, a charge back is created to QLT for [*].

Distributor will work directly with [*] to assist the customer with issues of reimbursement from
providers.

Distributor will provide [*] to QLT in order to trend sales and to facilitate processes such as
sales incentives and commissions to QLT Sales representatives. Distributor will provide [*].

The standard is next day air delivery for all orders shipped to customers,

Distributor will answer a minimum of [*] of incoming calls in [*].

Distributor will make available and follow procedures to ensure that inventory receipts, storage,
handling and order fulfillment are done in accordance with applicable law.

Distributor’s hours of operation in customer service are a minimum [*].

Distributor will [*] regarding an adverse event or complaint about the product. The [*] will be
[*].

Distributor agrees to perform [*] of staff in accordance with applicable regulations to assure
correct prices are offered subject to governing QLT policies and to assure all personnel are
courteous, are trained in governing QLT policies and requirements, and are fully responsive to
customer needs. On request, and in conformity with applicable laws and regulations, Distributor
will allow QLT personnel to participate in such monitoring activities as part of the service
evaluation.

Distributor will respond verbally to specific complaints from QLT customers, whether oral or in
writing, within [*]. Distributor will provide a full and detailed written report within [*]. In
the event that additional time is required for research, Distributor will advise QLT of the status
within [*] and complete the report within [*]. Distributor will take all reasonable and necessary
steps to prevent recurrence of service failures within its control, will regularly evaluate its own
service for QLT, will evaluate service levels and will also report its findings at regularly
scheduled review sessions.

Individual Distributor customer service agents assisting customers will be empowered to resolve
service complaints and problems.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

18

 

EXHIBIT B

Reporting Layout and Frequency of Transmission

Specialty Distributor Data Requirements

[*]

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

19

 

EXHIBIT C

QLT Returns Policy

QLT Ophthalmics, Inc. Returns Policy

Effective 1/1/2010

	1.	 	Authorization

	 	a)	 	Authorization to return outdated product can be issued by QLT Ophthalmics,
Inc.’s designated return goods processor, Integrated Commercialization Solutions, Inc.
(ICS), located at Suite 500, 420 International Boulevard, Brooks, KY, USA through their
Return program. To obtain a Wholesaler Return Goods Authorization Form and shipping labels
contact ICS’s Customer Service Department at 1-800-TBD.

	 	b)	 	Authorization to return product other than outdated product (i.e. in-dated
product, damaged goods, etc.) can only be issued by QLT Ophthalmics, Inc. through our
Return program. To request a Return Goods Authorization Form and shipping labels contact
QLT Ophthalmics’ Customer Service Department at 1-800-663-5486.

	 	c)	 	Sales Representatives are not authorized to accept merchandise or to approve the return
of merchandise.

	2.	 	Item Not Returnable from Wholesalers

	 	a)	 	If not in original package.

	 	b)	 	If package is opened, label removed, or has a broken seal.

	 	c)	 	If purchased on a non-returnable basis.

	 	d)	 	If involved in a fire sale or bankruptcy sale.

	 	e)	 	If deteriorated because of characteristics beyond the control of the manufacturer;
i.e., due to improper storage, heat, cold, water, smoke, fire, etc.

	 	f)	 	If returned one (1) year or more after the expiration date.

	 	g)	 	Merchandise damaged in transit — claim should be taken with carrier.

	 	h)	 	Any new product, package size, form or strength held for a period of less than six
months from the date of introduction to the wholesaler.

	 	i)	 	Saleable item which are deemed to be temporary reductions in wholesaler’s inventory.

	3.	 	Transportation charges for return of merchandise must be prepaid by the Wholesaler.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

20

 

	4.	 	Basis of credit for returned merchandise will be at the wholesaler’s acquisition cost (WAC)
in effect for that returned product’s lot number (WAC for that lot at the time of its sale).
Credit will not be issued for partial merchandise.

	5.	 	Special Instructions or Conditions:

	 	a)	 	Provide your DEA registration number

	 	b)	 	Each shipment of returned merchandise must be accompanied by a Wholesaler Return Goods
Authorization Form, supplied by QLT Ophthalmics, Inc or its designated return goods
processor, ICS. Unauthorized returns may be returned to the wholesaler freight collect.

	 	c)	 	QLT OPHTHALMICS, INC. RESERVES THE RIGHT TO DESTROY, WITHOUT RECOURSE, ALL RETURNED
PACKAGES.

	 	d)	 	It is suggested that wholesalers insure all return shipments. QLT Ophthalmics, Inc.
cannot be responsible for shipments lost in transit.

	 	e)	 	All QLT Ophthalmics, Inc. product is returnable for destruction, regardless of whether
or not it is eligible for credit reimbursement.

	 	f)	 	All QLT Ophthalmics, Inc. products are returned with the understanding that they are
subject to final review and evaluation by QLT Ophthalmics, Inc., and will be processed in
accordance with the most recent return goods policy in effect at the time the return is
received.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

21

 

EXHIBIT D

	I.	 	Discounts 

	 	A.	 	Discounts

	 	1.	 	All Non Federal Contract Price Customers are entitled to
receive the following Contract Price discount referenced in Table A-1 below.

[*]

Ex-Factory Prices and discount percentages, and therefore Contract Prices, are subject to

change without notice.

Table A-1:

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Ex-	 	 	 	 	 	 	 
	QLT	 	Generic	 	 	Package	 	 	 	 	 	 	Factory	 	 	Price	 	 	Contract	 
	Product	 	Name	 	 	Size	 	 	NDC#	 	 	Price	 	 	Discount	 	 	Price	 
	Visudyne
	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 

	 	2.	 	Contract Prices

QLT may change, at any time, the Ex-Factory Price without notice to
Distributor.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

22

 

EXHIBIT E

CONTINUING GUARANTY AND INDEMNIFICATION AGREEMENT

The undersigned does hereby guarantee to AmerisourceBergen Corporation and each of its subsidiary
companies and their successors that any food, drugs, devices, cosmetics, or other merchandise
(“Products”) now or hereafter shipped or delivered by or on behalf of the undersigned, its
subsidiaries, divisions, affiliated companies and representatives (“Guarantors”) to or on the order
of AmerisourceBergen Corporation or any of its subsidiaries under the terms of the Distribution
Services Agreement between QLT Ophthalmics, Inc. and ASD Specialty Healthcare, Inc. d/b/a Besse
Medical dated effective January 1, 2010 (the “Agreement”), will not be, at the time such shipment
or delivery, adulterated, misbranded, or otherwise prohibited under applicable federal, state and
local laws, including applicable provisions of the Federal Food, Drug and Cosmetic Act, 21 U.S.C.A.
§301 et seq., (“FDCA”), and its implementing regulations (“Applicable Laws”), as amended and in
effect at the time of shipment or delivery of such Products; and such Products are not, at the time
of such shipment or delivery, merchandise which may not otherwise be introduced or delivered for
introduction into interstate commerce under Applicable Laws, including, without limitation, FDCA
section 301 (21 U.S.C. §331); and such Products are merchandise which may be legally transported or
sold under the provisions of any other applicable federal, state or local law; and Guarantors
guarantee further that, in the case of food shipments, only those chemicals or sprays approved by
federal, state or local authorities have been used, and any residue in excess of the amount allowed
by any such authorities has been removed from such Products.

Guarantors hereby agree to defend, indemnify and hold AmerisourceBergen Corporation and each of its
subsidiaries harmless against any and all claims, losses, damages, and liabilities whatsoever (and
expenses connected therewith, including counsel fees), arising as a result of (a) any actual or
asserted violation of Applicable Laws or by virtue of which Products made, sold, supplied, or
delivered by or on behalf of Guarantors under the Agreement may be alleged or determined to be
adulterated, misbranded or otherwise not in full compliance with or in contravention of Applicable
Laws, (b) possession, distribution, sale and/or use of, or by reason of the seizure of, any
Products of Guarantors supplied in connection with the Agreement, including any prosecution or
action whatsoever by any governmental body or agency or by any private party, including claims of
bodily injury, death or property damage, (c) any actual or asserted claim that Guarantors’ Products
supplied in connection with the Agreement infringe any proprietary or intellectual property rights
of any person, including infringement of any trademarks or service names, trade names, trade
secrets, inventions, patents or violation of any copyright laws or any other applicable federal,
state or local laws, and (d) any actual or asserted claim of negligence, willful misconduct or
breach of contract; except to the extent that such claims, losses, damages and liabilities are
caused by any negligent act or omission of AmerisourceBergen Corporation or any of its subsidiary
corporations. Guarantors further agree to maintain primary and noncontributing Products Liability
Insurance of not less than U.S. $[*] per occurrence, Combined Single Limit (Bodily Injury and
Property Damage) including AmerisourceBergen Corporation and its subsidiary companies and their
successors as Additional Insureds, including a Broad Form Vendors Endorsement, and Guarantor shall
provide at least 30 days’ prior written notice to the Additional Insureds in the event of
cancellation or material reduction of coverage, and upon request promptly submit satisfactory
evidence of such insurance. All insurance coverage must be with a carrier and in a form acceptable
to AmerisourceBergen Corporation, at its sole reasonable discretion, including any deductible or
self-insurance risk retained by Guarantors. In combination with significant excess liability
insurance, any retained risk must be commercially reasonable, actuarially sound and acceptable to
AmerisourceBergen Corporation, at its sole reasonable discretion. Each Guarantor warrants that its
assets are sufficient to cover any self-insurance liability it assumes under this Agreement.
Provisions in this Continuing Guaranty and Indemnification Agreement are in addition to, and not in
lieu of, any terms set forth in the Agreement. In the event of any conflict between the language
of the Agreement and the language set forth herein, the language herein shall be controlling.

	 	 	 	 	 	 	 	 	 
	 	 	QLT Ophthalmics, Inc.	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By: 	 	 	 	 	 	 
	 	 	 	 	 	 
	 

	 	 	Name:	 	 	 	 
	 

	 	 	 	 	 	 

	 	 
	 

	 	 	Title:	 	 	 	 
	 

	 	 	 	 	 	 

	 	 
	 

	 	 	Date:	 	 	 	 	 
	 	 	 	 	 	 	 	 	 

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

23

 

Exhibit F

Approved Customers

[*]

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

24

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00180-of-00352.parquet"}]]